Close Menu

NEW YORK – Tempus on Monday announced a strategic collaboration with Janssen Research & Development in oncology clinical development programs and data science.

For this collaboration, Tempus said that it is developing a predictive machine-learning model to improve enrollment in biomarker-driven clinical trials for Janssen R&D, a unit of Johnson & Johnson's Janssen Pharmaceutica. According to Chicago-based Tempus, Janssen is looking for a method to speed up the identification of patients with specific tumor features that match the requirements of trials.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.